Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Singular Genomics Systems, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 4 Ropp Sam (Chief Commercial Officer) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 100,000 options to buy @ $0.5355, valued at $53.6k
08/15/2023 4 Kamdar Kim P. (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Sold 353,657 shares @ $0.5955, valued at $210.6k
Sold 77,991 shares @ $0.5696, valued at $44.4k
Sold 200,000 shares @ $0.5348, valued at $107k
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 SC 13G/A Flynn James E reports a 7.4% stake in Singular Genomics Systems, Inc.
08/14/2023 144 Form 144 - Report of proposed sale of securities:
08/11/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "### EX-99.1 Singular Genomics Systems, Inc. Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 505 $ - $ 1,368 $ - Cost of revenue 597 - 1,404 - Gross margin - - Operating expenses: Research and development 12,624 12,061 24,854 22,707 Selling, general and administrative 14,887 12,182 28,091 23,556 Total operating expenses 27,511 24,243 52,945 46,263 Loss from operations Other income : Interest expense Interest and other income 2,295 428 4,299 584 Total other income 2,025 261 3,770 275 Net loss $ $ $ $ Net loss per share: Basic and diluted net loss per share $ $ $ $ Weighted-average shares used to compute basic and diluted net loss per share 72,510,020 70,779,326 72,218,280 70,893,059 EX-99.1 Singular Genomics Systems, Inc. Bala..."
08/08/2023 4 Eisenberg Marcia (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 148,000 options to buy @ $0.747, valued at $110.6k
08/08/2023 3 Eisenberg Marcia (Director) has filed a Form 3 on Singular Genomics Systems, Inc.
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "###"
07/20/2023 8-K Quarterly results
05/26/2023 4 Kamdar Kim P. (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 74,000 options to buy @ $1.06, valued at $78.4k
05/26/2023 4 Mardis Elaine R (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 74,000 options to buy @ $1.06, valued at $78.4k
05/26/2023 4 Pellini Michael J (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 100,000 options to buy @ $1.06, valued at $106k
05/26/2023 4 Ryan Jason (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 74,000 options to buy @ $1.06, valued at $78.4k
05/26/2023 4 BARKER DAVID L (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Granted 74,000 options to buy @ $1.06, valued at $78.4k
05/18/2023 4 Glezer Eli N. (Chief Scientific Officer) has filed a Form 4 on Singular Genomics Systems, Inc.
Txns: Bought 170,000 shares @ $0.8172, valued at $138.9k
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Singular Genomics Systems, Inc. Statements of Operations Three Months Ended March 31, 2023 2022 Revenue $ 863 $ - Cost of revenue 807 - Gross margin 56 - Operating expenses: Research and development 12,230 10,645 Selling, general and administrative 13,204 11,375 Total operating expenses 25,434 22,020 Loss from operations Other income : Interest expense Interest and other income 2,004 156 Total other income 1,745 14 Net loss $ $ Net loss per share: Basic and diluted net loss per share $ $ Weighted-average shares used to compute basic and diluted net loss per share 71,926,412 71,011,041 EX-99.1 Singular Genomics Systems, Inc. Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 129,283 $ 74,266 Short-term investments 96,790 170,310 Accounts rec..."
04/20/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "Singular Genomics Systems, Inc. Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Revenue $ 765 $ - $ 765 $ - Cost of revenue 789 - 789 - Gross margin - - Operating expenses: Research and development 10,760 9,455 46,199 32,655 Selling, general and administrative 11,746 10,218 47,264 28,624 Total operating expenses 22,506 19,673 93,463 61,279 Loss from operations Other income : Interest expense Change in fair value of convertible promissory notes"
02/14/2023 SC 13G/A Glezer Eli N. reports a 6% stake in Singular Genomics Systems, Inc.
02/14/2023 SC 13G/A Revelation Alpine, LLC reports a 1.7% stake in Singular Genomics Systems, Inc.
02/10/2023 SC 13G/A Flynn James E reports a 9.1% stake in Singular Genomics Systems, Inc.
02/01/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy